product name Wogonin
Description: Wogonin (Vogonin), a natural and biologically-active flavonoid found in plants, has been reported to exhibit anticancer effects on several cancer cell types such as osteosarcoma, leukemia, breast cancer and glioma. Wogonin induced a G1 phase cell cycle arrest in HCT116 cells in a concentration- and time-dependent manner. Meanwhile, the cell cycle-related proteins, such as cyclin A, E, D1, and CDK2, 4 were down-regulated in wogonin-induced G1 cell cycle arrest. Furthermore, we showed that the anti-proliferation and G1 arrest effect of wogonin on HCT116 cells was associated with deregulation of Wnt/β-catenin signaling pathway.
References: Toxicology. 2013 Oct 4;312:36-47; Neurol Sci. 2015 Jul;36(7):1181-8.
284.26
Formula
C16H12O5
CAS No.
632-85-9
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 56 mg/mL (197.0 mM)
Water: <1 mg/mL
Ethanol: 8 mg/mL (28.1 mM)
Solubility (In vivo)
Synonyms
Vogonin
other peoduct :
| In Vitro |
In vitro activity: Wogonin induced a G1 phase cell cycle arrest in HCT116 cells in a concentration- and time-dependent manner. Meanwhile, the cell cycle-related proteins, such as cyclin A, E, D1, and CDK2, 4 were down-regulated in wogonin-induced G1 cell cycle arrest. Furthermore, we showed that the anti-proliferation and G1 arrest effect of wogonin on HCT116 cells was associated with deregulation of Wnt/β-catenin signaling pathway. Wogonin could potently promote Aβ clearance in the primary neural astrocytes and significantly decrease Aβ secretion in SH-SY5Y-APP and BACE1 cells through the mTOR/autophagy signaling pathway. wogonin not only inhibited the expression and interaction of TLR4, MyD88, and TAK1, but also reduced the activation of nuclear factor kappa B and mitogen-activated protein kinases pathway in LPS-treated DRG neurons. Moreover, wogonin significantly suppressed the release of pro-inflammatory mediators in LPS-induced DRG neurons, including cyclooxygenase-2, inducible nitric oxide synthases, interleukin (IL)-1β, IL-6, and tumor necrosis factor-alpha. Wogonin up-regulated transcription factor GATA-1 and enhanced binding between GATA-1 and FOG-1, thereby increasing expression of erythroid-differentiation genes. Wogonin also up-regulated the expression of p21 and induced cell cycle arrest. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Treatment with Wogonin reduced CLP-induced release of HMGB1 and sepsis-related mortality and pulmonary injury in mice. In vivo results indicated that wogonin attenuated LPS-induced histological alterations. Peripheral blood leucocytes decreased in the LPS-induced group, which was ameliorated by wogonin. In addition, wogonin inhibited the production of several inflammatory cytokines, including tumour necrosis factor-α, interleukin-1β (IL-1β) and IL-6. |
| Animal model | |
| Formulation & Dosage | |
| References | Toxicology. 2013 Oct 4;312:36-47; Neurol Sci. 2015 Jul;36(7):1181-8; Toxicol Appl Pharmacol. 2014 Nov 15;281(1):30-8; Oncotarget. 2014 Sep 30;5(18):8188-201; Immunology. 2014 Oct;143(2):241-57. |
